In March, the Food and Drug Administration (FDA) approved semaglutide (brand name: Wegovy) for just that purpose after a study published last November showed that the medication lowers certain peoples risk for those events by as much as 20%
Programme data have reported, for example, higher mean weight loss at 72 weeks with a GIP/GLP-1 regimen than with some GLP-1-only arms at different time pointscontext, population, and rescue/adherence rules all matter
Eric Topol (08:27): Well, inspired a whole industry is an understatement
doi: 10.1111/dom.14035 100 GastaldelliACusiKFernndez LandLBrayRBrouwersBRodrguez
[DOI] [PMC free article] [PubMed] [Google Scholar] 24.Hiramatsu A, Aikata H, Uchikawa S, et al
Some GLP-1 medications have evidence of cardiovascular risk reduction in specific patient groups